Butterfly Medical has also submitted a premarket approval application to the FDA.
|Videos|September 21, 2021
Novel MV140 vaccine is “game changing” for recurrent UTIs
Author(s)Urology Times staff
Advertisement
In this video, J. Curtis Nickel, MD, discusses the unmet need for a preventive treatment for patients with recurrent urinary tract infections (UTIs). At the 2021 AUA Annual Meeting, Nickel shared results from the groundbreaking study, "“
Nickel is a professor of the department of urology at Queen’s University and urologist at Kingston and Hotel Dieu General Hospitals, Kingston, Ontario, Canada.
Advertisement
Related to this article
Moderators and participants reviewed ARANOTE, ARACOG, and ARASEC data and how they inform individualized treatment for mCSPC.
Timothy N. Clinton, MD, recaps bladder cancer data from the 2026 AUA Northeastern Section meeting, including BOND-003 cretostimogene results and safety data on mitomycin intravesical solution.
Juan J. Andino, MD, MBA, discusses surgical decision-making in prolonged ischemic priapism and how ischemia duration affects erectile dysfunction risk and treatment timing.
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
Sandip Prasad, MD, MPhil, discusses ENVISION trial findings on mitomycin for intravesical solution and patient selection in clinical practice.
OpenFlo incorporates a design that modifies key mechanical features of conventional Foley catheters.
Study design discussions can help patients weigh personalized marketing claims, according to Jean Cunningham, PharmD, BCPS.
Advertisement
Advertisement
Trending on Urology Times
1
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
2
Butterfly Prostatic Retraction Device granted EU MDR certification for BPH
3
Variation in PSMA PET Adoption for Prostate Cancer Care
4
Matching mCSPC treatment to the patient, not just the trial data
5